To evaluate the steady-state systemic plasma concentrations of latanoprost acid following administration of latanoprost 0.005% (1.5 ug) in pediatric and adult subjects with glaucoma or ocular hypertension.

Pharmacokinetics and Safety

Inclusion Criteria:

• This study will enroll pediatric and adult subjects with glaucoma or ocular hypertension receiving treatment with latanoprost in either one or both eyes for at least two weeks.
• The pediatric subjects will be grouped by age (0 to <3 years, 3 to <12 years, 12 to 18 years).

Exclusion Criteria:

• Ocular inflammation/infection or a history of ocular inflammation/infection within 3 months prior to the screening visit.
• History of ocular trauma or surgery in either eye within 14-days of the screening visit.
• Use of continuous wear contact lenses.